Managing anticoagulant and antiplatelet drugs in patients who are receiving neuraxial anesthesia and epidural analgesia: a practical guide for clinicians

Techniques in Regional Anesthesia and Pain Management

Volumn 10, Issue 2, 2006, Pages 46-55

  Douketis, James D ^a   Dentali, Francesco ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Anticoagulants; Antiplatelet drugs; Epidural analgesia; Neuraxial anesthesia

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; CLOPIDOGREL; DALTEPARIN; DANAPAROID; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; FRESH FROZEN PLASMA; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTAMINE SULFATE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN INHIBITOR; TICLOPIDINE; TINZAPARIN; TIROFIBAN; VITAMIN K GROUP; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; DEEP VEIN THROMBOSIS; DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; ELECTIVE SURGERY; EMERGENCY SURGERY; EPIDURAL ANESTHESIA; EPIDURAL CATHETER; EPIDURAL HEMATOMA; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HEMOPHILIA; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK POPULATION; HUMAN; LOW DRUG DOSE; NAUSEA; PAIN CLINIC; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE ANALGESIA; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PREOPERATIVE CARE; RESPIRATORY FAILURE; SPINAL ANESTHESIA; SPINAL HEMATOMA; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; VISUAL ANALOG SCALE; VOMITING;

EID: 33745684860     PISSN: 1084208X     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.trap.2006.04.004     Document Type: Article

References (41)

1. Lawton M.T., Porter R.W., Heiserman J.E., et al. Surgical management of spinal epidural hematoma. relationship between surgical timing and neurological outcome. J Neurosurg 83 (1995) 1-7
2. Hirsh J., and Raschke R. Heparin and low-molecular-weight heparin. the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 suppl (2004) 188S-203S
3. Basu D., Gallus A., Hirsh J., et al. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 287 (1972) 324-327
4. Fareed J., Jeske W., Hoppensteadt D., et al. Low-molecular-weight heparins. pharmacological profile and product differentiation. Am J Cardiol 82 (1998) 3L-10L
5. Hirsh J., and Levine M.N. Low molecular weight heparin. Blood 79 (1992) 1-17
6. Warkentin T.E., Levine M.N., Hirsh J., et al. Heparin induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 332 (1995) 1330-1335
7. Turpie A.G., Gallus A.S., and Hoek J.A. Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 344 (2001) 619-625
8. Ansell J., Hirsh J., Poller L., et al. The pharmacology and management of the vitamin K antagonists. the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 suppl (2004) 204S-233S [Published erratum in Chest 127:415-416, 2005]
9. Shields R.C., McBane R.D., Kuiper J.D., et al. Efficacy and safety of intravenous phytonadione (vitamin K1) in patients on long-term oral anticoagulant therapy. Mayo Clin Proc 76 (2001) 260-266
10. Patrono C., Coller B., FitzGerald G.A., et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 suppl (2004) 234S-264S
11. Coukell A.J. Clopidogrel. Drugs 54 (1997) 745-750
12. Crowther M.A., Berry L.R., Monagle P.T., et al. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 116 (2002) 178-186
13. Warkentin T.E., and Crowther M.A. Reversing anticoagulants both old and new. Can J Anaesth 49 (2002) S11-S25
14. Landow L. A synthetic pentasaccharide for the prevention of deep-vein thrombosis. [Letter] N Engl J Med 345 (2001) 291-292
15. Turpie A.G., Gallus A.S., and Hoek J.A. Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 345 (2001) 292 [Letter]
16. Odoom J.A., and Sih I.L. Epidural analgesia and anticoagulant therapy. experience with one thousand cases of continuous epidurals. Anaesthesia 38 (1983) 254-259
17. Horlocker T.T., Wedel D.J., and Schlicting J.L. Postoperative epidural analgesia and oral anticoagulant therapy. Anesth Analg 79 (1994) 89-93
18. Wu C.L., and Perkins F.M. Oral anticoagulant prophylaxis and epidural catheter removal. Reg Anesth Pain Med 21 (1996) 517-524
19. Woolson S.T., Robinson R.K., Khan N.Q., et al. Deep venous thrombosis prophylaxis for knee replacement. warfarin and pneumatic compression. Am J Orthop 27 (1998) 299-304
20. Badenhorst C.H. Epidural hematoma after epidural pain control and concomitant postoperative anticoagulation. Reg Anesth Pain Med 21 (1996) 272-273
21. CLASP (Collaborative Low-Dose Aspirin Study in Pregnancy) Collaborative Group. CLASP. a randomized trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet 343 (1994) 619-629
22. Dyke C.M. Safety of glycoprotein IIb-IIIa inhibitors. a heart surgeon's perspective. Am Heart J 138 (1999) 307-316 [Review]
23. Rodgers A., Walker N., Schug S., et al. Reduction of postoperative mortality and morbidity with epidural or spinal anesthesia. results from overview of randomised trials. Br Med J 321 (2000) 1493
24. Rigg J.R., Jamrozik K., Myles P.S., et al. Epidural anesthesia and analgesia and outcome after major surgery. a randomised trial. Lancet 359 (2002) 1276-1282
25. Choi P., Bhandari M., Scott J., et al. Epidural analgesia for pain relief following hip or knee replacement. Cochrane Database Syst Rev 3 (2003) CD003071
26. Geerts W.H., Pineo G.F., Heit J.A., et al. Prevention of venous thromboembolism. Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 338S-400S
27. Hull R.D., Pineo G.F., Stein P.D., et al. Timing of initial administration of low-molecular weight heparin prophylaxis against deep vein thrombosis in patients following hip arthroplasty. Arch Intern Med 161 (2001) 1952-1960
28. Kakkar V.V., Flanc C., Howe C.T., et al. Natural history of postoperative deep-vein thrombosis. Lancet 1 (1969) 230-232
29. Horlocker T.T., and Heit J.A. Low molecular weight heparin. biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines or regional anesthetic management. Anesth Analg 85 (1997) 874-885
30. Lumpkin M.M. FDA Public Health Advisory. Reports of epidural or spinal hematomas with the concurrent use of low molecular weight heparin and spinal/epidural anesthesia or spinal puncture. Anesthesiology 88 (1999) 27A-28A
31. Schroeder D.R. Statistics. detecting a rare adverse drug reaction using spontaneous reports. Reg Anesth Pain Med 23 suppl 2 (1998) 183-189
32. Horlocker T.T. Low molecular weight heparin and neuraxial anesthesia. Thromb Res 101 (2001) V141-V154
33. Tryba M., and Wedel D.J. Central neuraxial block and low molecular weight heparin (enoxaparin). Lessons learned from two different dosage regimens in two continents. Acta Anaesthesiol Scand 41 suppl 111 (1997) 100-104
34. Canavaro D. Periopertive use of low-molecular-weight heparin (letter). J Bone Joint Surg 82-A (2000) 1673-1674
35. Douketis J.D., Kinnon K., and Crowther M.A. Anticoagulant effect at the time of epidural catheter removal in patients receiving twice-daily or once-daily low-molecular-weight heparin and continuous epidural analgesia after orthopedic surgery. Thromb Haemost 88 (2002) 37-40
36. Hirsh J., Warkentin T.E., Shaughnessy, et al. Heparin and low-molecular-weight heparin. mechanism of action, pharmacokinetics, dosing, monitoring, efficacy, safety. Chest 119 (2001) 64S-94S
37. Horlocker T.T., Wedel D.J., Benzon H., et al. Regional anesthesia in the anticoagulated patient. Defining the risks. Reg Anesth Pain Med 29 suppl (2004) 1-12
38. Schwander D., and Bachmann F. Herparine et anesthesies medullaires. analyse de decision. Ann Fr Anesth Reanim 10 (1991) 284-296
39. Wang J., and Douketis J.D. Safety of co-administered epidural analgesia and low-molecular-weight heparin after orthopedic surgery. Blood 104 (2004) 198a
40. Boneau B., Necciari J., Cariou R., et al. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org 31540) with high affinity to antithrombin III in man. Thromb Haemost 74 (1995) 1486-1473
41. Turpie A.G., Bauer K.A., Eriksson B.I., et al. Fondaparinux vs. enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 162 (2002) 1833-1840